Welcome to our dedicated page for VSee Health SEC filings (Ticker: VSEE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The VSee Health, Inc. (NASDAQ: VSEE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a telehealth technology and services company in the health information services sector, VSee uses its filings to report on business operations, capital structure, financing arrangements, and Nasdaq listing matters.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for information on VSee’s healthcare technology and telehealth services segments, revenue composition, costs, and risk factors. These core filings outline how the company describes its AI-powered telehealth platform, high-acuity virtual care services, and digital health offerings that integrate secure video, device data, and EHR connectivity for hospital systems, health networks, employers, and enterprise partners.
VSee’s current reports on Form 8-K document material events such as private placements of common stock and warrants, convertible note agreements, warrant exchanges, equity line of credit arrangements, and amendments tied to Nasdaq stockholders’ equity requirements. Recent 8-K and 8-K/A filings describe steps the company has taken to address Nasdaq Listing Rule 5550(b)(1), including capital transactions and conversions of outstanding instruments, as well as governance items like annual meeting scheduling and bylaw amendments affecting quorum.
Through this page, users can also locate proxy materials on Schedule 14A, which detail proposals for director elections, auditor ratification, equity incentive plans, and adjournment authority, along with information on voting rights for common and preferred stock. For those monitoring ownership and compensation, insider transactions and related disclosures can be reviewed via the relevant SEC forms where available.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand complex capital structures, financing terms, and operational disclosures without replacing the full text of the official filings.
VSee Health, Inc. registers 33,808,195 shares of Common Stock for resale under a prospectus supplement, including shares issuable upon conversion or exercise of preferred stock, warrants and pre-funded warrants.
The supplement ties to private placements that closed on December 1, 2025 and December 9, 2025, and updates the prospectus with proxy and Form 8-K disclosures. The company sought and obtained stockholder approval under Nasdaq Listing Rule 5635(d) for issuance of warrants exercisable for up to 19,672,130 shares. Shares outstanding were reported as 43,244,355 as of February 2, 2026.
VSee Health, Inc. reported that stockholders approved a key share issuance related to a private placement at a special meeting held on March 2, 2026. The meeting had a quorum, with 21,824,877 votes represented, or 50.46% of shares entitled to vote.
Stockholders approved issuing common shares to certain holders of warrants to purchase up to 19,672,130 shares of common stock, as required under Nasdaq Listing Rule 5635(d). The proposal passed with 14,109,726 votes for, 7,698,963 against, and 16,188 abstentions. An adjournment proposal was also approved but withdrawn because the main private placement proposal received sufficient support.
VSEE HEALTH, INC. director-related entity FWE Capital LLC converted convertible promissory notes into shares of common stock. On February 23, 2026, the LLC acquired 759,916 shares of common stock at $0.3200 per share and 105,251 shares at $0.6500 per share through derivative conversions.
After these conversions, FWE Capital LLC held 1,147,564 shares and 387,648 shares of VSEE common stock in two separate indirect ownership positions for reporting person David L. Wickersham. The filing notes that the underlying notes included both principal and interest.
VSee Health, Inc. Schedule 13G/A discloses that the reporting persons beneficially own 833,331 shares, representing 2.0% of the class. The reported position consists of Public Warrants to purchase 702,896 shares plus 130,435 shares issuable under a Warrant Exchange Agreement. The percentage calculation references 40,230,845 shares outstanding as of February 2, 2026, plus the 833,331 issuable shares.
VSee Health, Inc. entered a managed services agreement with GoMyRx, Inc. under which VSee will provide platform administration, customer support, vendor coordination, and reporting services. VSee will bill GoMyRx monthly for actual expenses plus a 10% markup, and the agreement runs through December 26, 2027, with optional month-to-month extensions for six months.
Separately, VSee agreed to purchase $2.0 million of GoMyRx common stock from Go Biz Holdings, LLC in a private transaction, representing a 10% ownership stake in GoMyRx. The shares are restricted securities issued under Section 4(a)(2) and Rule 506 of Regulation D.
VSee Health, Inc. director David L. Wickersham reported an "other" insider transaction involving 100,000 shares of common stock at a stated value of $2.00 per share. According to the filing, he received these shares from Co-Chief Executive Officer Imoigele Aisiku as full repayment of a $200,000 personal loan. Following this transfer, Wickersham directly holds 214,000 shares of VSee Health common stock.
VSee Health, Inc. director and Co-Chief Executive Officer Aisiku Imoigele reported two stock transfers used to repay personal loans. On August 15, he transferred 25,000 common shares at $2.00 per share in full satisfaction of a $50,000 personal loan. On August 14, he transferred 100,000 common shares at $2.00 per share to board member David Wickersham to fully repay a separate $200,000 personal loan made to him by Mr. Wickersham. Following these transactions, his reported direct holdings remained above 3.2 million common shares.
VSee Health, Inc. ownership disclosure: Armistice Capital, LLC and Steven Boyd report shared beneficial ownership of 1,889,308 shares of Common Stock, representing 9.99% of the class as of 12/31/2025.
The filing states Armistice Capital is investment manager of the Master Fund, which directly holds the shares, and that Mr. Boyd, as managing member, may be deemed to beneficially own those shares. The Master Fund disclaims beneficial ownership by virtue of its Investment Management Agreement with Armistice Capital. Signatures are dated 02/17/2026.
VSee Health, Inc. has called a virtual special meeting on March 2, 2026 to ask stockholders to approve a prior private placement under Nasdaq Listing Rule 5635(d). The company sold 9,836,065 shares of common stock (or pre-funded warrants) plus warrants for up to 19,672,130 shares in a November 2025 private offering, raising approximately $6 million at $0.61 per share.
Stockholders are being asked to approve the potential issuance of the warrant shares, which would exceed 20% of currently outstanding common stock, and to authorize possible adjournment of the meeting if more time is needed to gather votes. Common and Series A Preferred holders of record on February 2, 2026 are entitled to vote.
VSEE Health, Inc. received an amended Schedule 13G/A from a group led by Dominion Capital and Ascent Partners reporting reduced beneficial ownership of its common stock. The group now beneficially owns 1,014,654 shares, or about 2.97% of the company, based on 33,193,140 shares outstanding as of December 26, 2025.
The position includes 100,000 shares issued as closing shares under a March 20, 2025 promissory note and common stock purchase warrants exercisable for additional shares. The filers state this is an exit filing because they no longer own more than 5% and certify the holdings are not for control purposes.